$BJDX

HRT FINANCIAL LP sold $49K of BJDX

HRT FINANCIAL LP sold 34,938 shares of Bluejay Diagnostics, Inc. (BJDX) at $1.40 on 2026-07-10.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jul 13, 2026, 7:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 7:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BJDX
Neutral
medium confidence
Mentioned
$BJDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BJDXNeutralLow
01

Why it matters

The newest fact is the reported open-market sale by a 10% owner at a specified price and share count; it may influence short-term sentiment but does not change operating outlook based on the provided text.

02

Market read

Traders may monitor for follow-on insider activity or interpret the sale as mild negative sentiment, but there is no new fundamental catalyst in the text.

03

What to watch

No 10b5-1 plan is stated, but the article also lacks context on total holdings, prior sales cadence, or whether the sale was part of broader portfolio rebalancing.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-13, sale dated 2026-07-10

Background

This is an SEC Form 4 insider transaction disclosure for Bluejay Diagnostics, Inc. (BJDX).

Company-level read

Ticker impact

$BJDXNeutralMedium confidence
Context

HRT Financial LP, a 10% owner, filed a Form 4 selling 34,938 BJDX shares at $1.40 on 2026-07-10.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing is a routine insider sale with no 10b5-1 plan and no accompanying company-specific news (earnings, guidance, trials, deals). Size is moderate, so impact is usually contained.

Market effects

No sector read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The sale may be liquidity-driven and not a bearish signal, especially since the filing provides no rationale or linkage to company performance.

Key entities

  • Bluejay Diagnostics, Inc.

    Subject of the Form 4 insider sale disclosure (BJDX).

  • HRT Financial LP

    10% owner who sold 34,938 shares in an open-market transaction.

  • SEC Form 4

    Primary-source insider transaction report filed on 2026-07-13.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

$BJDXMed

Bluejay Diagnostics, Inc.: Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony IL-6 Toward Regulatory Submission and Commercialization

Bluejay Diagnostics (NASDAQ: BJDX) reported Q2 2026 results and said its SYMON-II pivotal study completed enrollment of 750 patients. The company is progressing toward analytical and clinical validation for a planned FDA 510(k) submission and signed a US manufacturing contract. Cash rose to about $9.6M at June 30, 2026 from $5.2M at Dec. 31, 2025, after a June private placement.

$BJDXMed

Bluejay Completes Enrollment In SYMON-II Sepsis Study

Bluejay Diagnostics (BJDX) said it completed patient enrollment in its pivotal SYMON-II sepsis study, reaching 750 patients ahead of schedule. The multicenter validation evaluates its Symphony IL-6 test for predicting 28-day mortality risk in ICU sepsis patients. The company plans data analysis and expects results to support an FDA 510(k) submission.

$BJDXMedAI 8/10

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics (NASDAQ: BJDX) said it closed a private placement under Nasdaq rules, selling 3,655,917 shares (or pre-funded warrants) plus Series G and short-term Series H warrants at $2.325 per share. Gross proceeds were $8.5 million, with up to ~$15.2 million more if warrants are fully exercised for cash. The company expects net proceeds to fund operations into Q1 2027.